In the BioHarmony Drug Report Database
Differin (adapalene) is a small molecule pharmaceutical. Adapalene was first approved as Differin on 1996-05-31. It is used to treat acne vulgaris in the USA. The pharmaceutical is active against retinoic acid receptor beta and retinoic acid receptor gamma. In addition, it is known to target retinoic acid receptor alpha. Epiduo’s patents are valid until 2028-05-31 (FDA).
Image (chem structure or protein)